AlphAIalphai — Financial news for AI agents
calcalistech.comSEP 22 min read$TEVA

Teva moves closer to a drug for celiac disease with positive Phase 2 results

Teva reported positive Phase 2a trial results for TEV-408, an experimental treatment for celiac disease. The trial met its primary endpoint, showing significant prevention of intestinal damage from gluten. Teva estimates potential annual revenue of $1 billion for the celiac indication if approved. The drug is also being developed for vitiligo, with a separate trial showing encouraging results. Teva could receive up to $500 million from Royalty Pharma for the vitiligo program.

Original reporting
calcalistech.com
Published Sep 2, 2026, 3:39 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 3, 2026, 5:24 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Teva moves closer to a drug for celiac disease with positive Phase 2 results — source image
Source · calcalistech.com
Decision brief

The 30-second read

$TEVABullishMed
01

Why it matters

Positive Phase 2a data could increase R&D investment and partnership interest.

02

Market read

First report of pivotal trial results for a large‑addressable autoimmune indication.

03

What to watch

Potential competition from other IL‑15 targeting programs and the need for larger Phase 2b/Phase 3 data.

Relevance 9/10Novelty 8/10Timing: today

Background

Celiac disease currently has no approved drug; Teva's TEV-408 aims to address the underlying immune pathway.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

Teva reported positive Phase 2a results for its experimental antibody TEV-408 for celiac disease, meeting primary endpoint.

Expected impact

Potential upside as investors price in future revenue opportunity.

Evidence & confidence

First disclosure of pivotal trial results for a large‑addressable market; market typically reacts to such data.

Market effects

Sector

Strengthens the biotech sector's pipeline narrative and may lift peers developing autoimmune therapies.

Regional

US biotech stocks could see modest gains.

Global

Highlights potential new treatment for a worldwide disease affecting ~1% of the population.

Counterpoint

What could challenge this read

Skeptics may note the long timeline to market (2034) and risk of later-stage failures.

Key entities

  • Company
    Teva Pharmaceutical Industries Ltd.

    Developer of TEV-408.

  • Company
    Royalty Pharma

    Partner for TEV-408 vitiligo program.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 4
$TEVAMed

Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?

Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.

finance.yahoo.com3 min
SEP 4
$TEVAMed

S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline

S&P Global Ratings upgraded Teva Pharmaceutical's long-term issuer credit rating to BBB- from BB+, reflecting strong financial performance and debt reduction. This is the third upgrade in recent months, with Teva now holding investment-grade ratings from all major agencies. The company's CFO attributed the upgrades to successful execution of its growth strategy and improved financial profile.

globenewswire.com1 min
SEP 2
$TEVAMedAI 8/10

Teva Stock Drops As Celiac Trial Fails To Impress - TipRanks.com

Teva Pharmaceutical's (TEVA) stock declined despite early-stage positive results from a Phase 2a trial of TEV-408 for celiac disease. Investors were unimpressed due to the lack of later-stage data or a commercialization timeline. The company is focusing on specialty medicines and biosimilars to stabilize growth but faces challenges from debt and generic revenue pressure.

tipranks.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Drug Rises to the Gluten Challenge, Stopping Intestinal Damage in Celiac Disease Trial

Teva Pharmaceutical Industries' experimental drug TEV-53408 met its main goal in a mid-stage trial, preventing intestinal damage in celiac disease patients. The Phase 2a study showed significant improvement in intestinal health and symptom scores compared to placebo. Teva plans further studies and projects peak sales of $1.5B-$2B for the drug, which targets the IL-15 pathway. The company has a deal with Royalty Pharma for up to $500M in support.

medcitynews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Reports Positive Phase 2a Results For TEV-408 In Celiac Disease

Teva Pharmaceutical (TEVA) reported positive Phase 2a trial results for TEV-408, an anti-IL-15 monoclonal antibody, in celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage. TEV-408 also reduced inflammation and improved patient-reported outcomes. The company plans to present further data and host an investor call. TEVA stock closed at $36.19, up 0.39%, and is up 0.77% in pre-market trading.

rttnews.com2 min
SEP 2
$TEVAMedAI 8/10

Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408

Teva Pharmaceutical (TEVA) reported positive topline results from a Phase 2a study of TEV 408, an anti-interleukin-15 monoclonal antibody, for treating celiac disease. The study met its primary endpoint, showing significant prevention of gluten-induced intestinal damage compared to placebo. The company plans to present further data at a future scientific meeting. TEVA shares rose 2.96% in pre-market trading.

rttnews.com1 min